
Case builds for Biogen, Stoke's Dravet syndrome drug
Hopes have risen for a new treatment for severe childhood epilepsy Dravet syndrome, on the back of new data for Biogen and Stoke's zorevunersen.
Newsletters and Deep Dive digital magazine
Hopes have risen for a new treatment for severe childhood epilepsy Dravet syndrome, on the back of new data for Biogen and Stoke's zorevunersen.
AbbVie has signed another deal in its effort to build an industry-leading position in multispecific antibodies for blood cancers.
A new US startup, called Varda Space Industries, has raised $187 million in financing for a bold plan to manufacture medicines in orbit.
The FDA says publishing complete response letters for medicines is an act of "radical transparency," but it is not as revolutionary as it seems.
As existing antibiotics become less effective, we edge closer to a future where routine infections & minor injuries could once again become high risk.
Editor's Picks
Newsletters and Deep Dive
digital magazine